Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

RTN4 3'-UTR insertion/deletion polymorphism and susceptibility to non-small cell lung cancer in Chinese Han

De-Yi Lu1, Xu-Hua Mao, Ying-Hui Zhou

  • 1Department of Biochemistry and Molecular Biology, Medical School, Soochow University, Suzhou, Jiangsu, China E-mail : 1594662939@qq.com; mhwang@suda.edu.cn.

Asian Pacific Journal of Cancer Prevention : APJCP
|July 22, 2014
PubMed

Insights

The reticulon-4 (RTN4) gene

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Nogo protein, encoded by reticulon-4 (RTN4), influences cell apoptosis, particularly in tumor cells.
  • Single nucleotide polymorphisms (SNPs) in RTN4 can affect gene expression and cancer predisposition.
  • The RTN4 3'-UTR CAA insertion/deletion polymorphism (rs34917480) is linked to various cancer types.

Purpose of the Study:

  • To investigate the association between the RTN4 rs34917480 polymorphism and non-small cell lung cancer (NSCLC) susceptibility.
  • To analyze the influence of age, sex, and smoking status on this association in the Chinese population.

Main Methods:

  • A case-control study was conducted with 411 NSCLC patients and 471 healthy controls from the Chinese population.
  • Genotyping of the RTN4 rs34917480 polymorphism was performed.
  • Statistical analysis, including genotype and allele model comparisons, was used to assess NSCLC risk.

Main Results:

  • Significant differences in genotype distributions were observed between NSCLC cases and controls (p=0.014).
  • The 'del' allele of the rs34917480 polymorphism was associated with a significantly increased risk of NSCLC.
  • This increased risk was more pronounced in individuals over 60 years old, males, and smokers.

Conclusions:

  • The RTN4 rs34917480 CAA insertion/deletion polymorphism is a contributing factor to non-small cell lung cancer risk in the Chinese population.
  • Age, sex, and environmental exposures like smoking modulate the carcinogenic effects of this polymorphism.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

555
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.4K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K